Kythera Biopharmaceuticals Announces Preliminary Two-Year Follow-Up Study Results and Poster Presentation of Phase 2B Data from Investigational Fat Reduction Drug at ASDS

--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc.:

What: Oral Presentation of Preliminary Two-Year Long-Term Follow-Up Study Results from Phase 2 Trials with ATX-101 for the Reduction of Localized Fat.

Poster Presentation of Results from a Phase 2B Study with ATX-101 Using Investigator, Subject and Magnetic Resonance Imaging Assessments